emporia: Smartphones Now More Popular Than Landline Phones Among the Over 60s
4.9.2019 10:00:00 EEST | Business Wire | Press release
Three out of four senior citizens would rather live without a conventional landline telephone than their smartphone. These are the findings of the 2019 Senior Citizens Survey: Smart Technology - Everyday, conducted by emporia Telecom in partnership with the German Senior Citizens League, in which 500 smartphone owners aged over 60 were interviewed.
Digital communication has become a simple matter of fact for many older people . One significant reason according to 83 percent of interviewees is: it is easier to maintain contact with family and friends via a smartphone.
According to the survey, three-quarters of senior citizens don’t want to be without their smartphone when they are out and about. It's also essential to them when travelling. It means that they always have useful information to hand, like weather forecasts and maps.
But it's far from every senior citizen that enjoys the benefits of the digital world. “75 million senior citizens in the EU today still don't own a smartphone. Yet there is an ever-increasing number of day-to-day activities that can only be performed with one. It's important to keep up to pace with modern communication technology so that you don’t suddenly find yourself cut adrift,” says Eveline Pupeter, owner and CEO of emporia Telecom. “It's our mission to guide older people into the digital future.”
The survey clearly identifies the concerns and difficulties experienced by senior citizens. Many older people worry about being left behind in a technology-driven world. For example, they wonder if they will even be able to perform daily errands and tasks such as using banking services, dealing with public authorities or buying bus and train tickets just as easily as they could before. “There's no stopping the progress of technology, but technology can also be simplified,” says emporia boss Eveline Pupeter. “We are seeking to gradually break down the fear of interacting with technology, and to help get the older generation up and ready for the future with user-friendly smartphones.
emporia is presenting two innovations simultaneously this September: The emporiaSMART.3 and the emporiaSMART.3mini. Despite their simplicity of use, both smartphones are fully intelligent, highly complex and state-of-the-art devices.
The emporiaSMART.3 is an easy-to-use top-class smartphone equipped with all the usual features such as two cameras, a powerful battery, Wi-Fi, Bluetooth, GPS, 5.5” screen, Type-C charging etc. It has a simple interface and mechanical home button and it’s also dust and splash-proof, compatible with hearing aids, has a sound amplifier, emergency call button, charging station and learning manual.
The SMART.3mini is something special. It was developed specially for men who wanted a compact smartphone that would easily fit into their trouser or shirt pocket. The SMART.3mini features a 4.95 inch touchscreen, meaning it's still easy to see and use. Spec-wise he mini is every bit the equal of its big brother, the SMART.
Talking about her mission, Eveline Pupeter says: “75 million of 65+ senior citizens in the EU still don't have a smartphone. It's emporia's goal to guide this generation into the digital future. Because being “smart” has nothing to do with age.”
The Linz-based manufacturer has a dual approach towards bringing digitalisation to the older generation. Its hardware and software solutions are precisely tailored for this target group. But it has also developed new training courses (such as Smartphones for Beginners, WhatsApp courses, Staying Secure on the Smartphone) to make it easier for senior citizens to get started.
emporia, the technology leader
emporia is an Austrian company that develops, manufactures and markets mobile telephones, smartphones and apps for the older generation. emporia’s products also include a wide range of accessories and landline telephones. Founded in 1991, emporia now operates in more than 30 countries around the world. The company is wholly owned by Eveline Pupeter who runs the business, together with her experienced management team. emporia employs 100 people. Its head office is located in the city of Linz on the banks of the Danube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005082/en/
Contact information
Walter Deil
+43 670 7010 322
deil@emporia.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
